Thromboprophylaxis in Pregnant Women with COVID-19: An Unsolved Issue

Valentin Nicolae Varlas, Roxana Georgiana Borș, Mihaela Plotogea (), Madalina Iordache, Claudia Mehedințu and Monica Mihaela Cîrstoiu
Additional contact information
Valentin Nicolae Varlas: Department of Obstetrics and Gynecology, Filantropia Clinical Hospital, 011171 Bucharest, Romania
Roxana Georgiana Borș: Department of Obstetrics and Gynecology, Filantropia Clinical Hospital, 011171 Bucharest, Romania
Mihaela Plotogea: Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu St., 050451 Bucharest, Romania
Madalina Iordache: Doctoral School, “Carol Davila”, University of Medicine and Pharmacy, 4192910 Bucharest, Romania
Claudia Mehedințu: Department of Obstetrics and Gynecology, Filantropia Clinical Hospital, 011171 Bucharest, Romania
Monica Mihaela Cîrstoiu: Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu St., 050451 Bucharest, Romania

IJERPH, 2023, vol. 20, issue 3, 1-19

Abstract: SARS-CoV-2 infection in pregnant women is of growing interest due to controversy over the use of antiplatelet and/or anticoagulant drugs during pregnancy and postpartum. Pregnant women are susceptible to develop severe forms of viral infections due to pregnancy-related immune alterations, changes in lung functions, and hypercoagulability. The association of pregnancy with SARS-CoV-2 infection can cause an increased incidence of thrombotic complications, especially in the case of patients with some genetic variants that favor inflammation and thrombosis. Compared to the general population, pregnant women may be at increased risk of thrombotic complications related to COVID-19. The lack of extensive clinical trials on thromboprophylaxis and extrapolating data from non-pregnant patients lead to major discrepancies in treating pregnant women with COVID-19. Currently, a multidisciplinary team should determine the dose and duration of prophylactic anticoagulant therapy for these patients, depending on the disease severity, the course of pregnancy, and the estimated due date. This narrative review aims to evaluate the protective effect of thromboprophylaxis in pregnant women with COVID-19. It is unknown at this time whether antiplatelet or anticoagulant therapy initiated at the beginning of pregnancy for various diseases (preeclampsia, intrauterine growth restriction, thrombophilia) offers a degree of protection. The optimal scheme for thromboprophylaxis in pregnant women with COVID-19 must be carefully established through an individualized decision concerning gestational age and the severity of the infection.

Keywords: COVID-19; thrombosis; antiplatelet; anticoagulant; pregnancy; low-molecular-weight heparin; thromboprophylaxis (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/3/1949/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/3/1949/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2023:i:3:p:1949-:d:1042649

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().